

**CORONA Remedies Limited**

(Formerly known as CORONA Remedies Private Limited)

Regd. Office: CORONA House

C- Mondeal Business Park, Near Gurudwara, S.G. Highway,
Thaltej, Ahmedabad 380 059. Gujarat, India.

Tele.: +079 - 40233000

Online at : Info@coronaremedies.com

website : www.coronaremedies.com

CIN : L24231GJ2004PLC044656

May 11, 2026

To,
Listing Operation Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai-400001
(Scrip Code: 544644)

To,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G, Bandra Kurla
Complex, Bandra (East), Mumbai-400051
(SYMBOL: CORONA)

Dear Sir / Madam,

Sub.: Outcome of the Board Meeting**Ref.: Regulation 30 and 33 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

We would like to inform that the Board at its meeting held today, i.e. May 11, 2026 has, inter alia, considered the following:

- (i) On recommendation of Audit Committee, approved the Audited Standalone and Consolidated Financial Results along with Audit Reports of the Company for the fourth quarter and year ended March 31, 2026 **"Annexure A"**.

Further, pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Chapter III, Section III-A, clause (D), sub-clause 19 of the SEBI master circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, we declare and confirm that the Auditor's reports on Standalone and Consolidated Financial Results are unmodified.

- (ii) Recommended final dividend of ₹ 10/- (100%) per equity share of face value of ₹ 10/- each to the shareholders for their approval at the ensuing Annual General Meeting of the Company.

Pursuant to the Regulation 42 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it is hereby informed that the Company has fixed Friday, June 19, 2026 as Record Date for the purpose of determining entitlement of the members of the Company to receive Final Dividend of ₹ 10/- (100%) per equity share of ₹ 10/- each for the Financial year 2025-26. The said Dividend, if declared by the shareholders at the ensuing Annual General Meeting, shall be paid on or before August 07, 2026, subject to deduction of tax at source as applicable.

- (iii) On recommendation of Audit Committee, the Board of Directors approved the recommendation for appointment of M/s. Walker Chandiook & Co LLP, Chartered Accountants (Firm Registration Number: 001076N/N500013) as Statutory Auditor of the Company for a period of five consecutive years commencing from conclusion of the 22nd Annual General Meeting to be held for the Financial year 2025-26 until the conclusion of the 27th Annual General Meeting to be held for the Financial year 2030-31, to conduct the Statutory Audit of the Company for a period of five consecutive financial years (i.e. from F.Y. 2026-27 to F.Y. 2030-31), subject to approval of Members in the ensuing Annual General Meeting of the Company.

- (iv) On recommendation of Audit Committee, the Board of Directors approved the recommendation for re-appointment of M/s. Dhara Patel, peer reviewed Company Secretary Firm (ACS- 29198/C.P. No.-10979) as the Secretarial Auditor of the Company for a period of five consecutive years commencing from the Financial year 2026-27, subject to approval of Members at the ensuing Annual General Meeting of the Company.
- (v) On recommendation of Audit Committee, the Board of Directors approved appointment of M/s. Shah & Shah Associates, Chartered Accountants (Firm Registration Number: 113742W) as Internal Auditor of the Company for the Financial Year 2026-27.
- (vi) On recommendation of Audit Committee, the Board of Directors approved re-appointment of M/s. Manish B. Analkat (Registration No. 19378), as Cost Auditor of the Company for the Financial Year 2026-27.
- (vii) On the recommendation of the Nomination and Remuneration Committee, the Board of Directors approved recommendation for re-appointment of Dr. Kirtikumar Mehta (DIN: 00385658) as Non Executive Director and Chairman of the Company, for a term of five (5) consecutive Financial Years with effect from April 01, 2027, subject to approval of shareholders of the Company at the ensuing Annual General Meeting. Further, pursuant to BSE Circular no. LIST/COMP/14/2018-19 and NSE Circular no. NSE/CML/2018/24, both dated June 20, 2018, it is hereby also affirmed that Dr. Kirtikumar Mehta is not debarred from holding the office of director by virtue of any SEBI order or any other authority.
- (viii) A Press Release on Financial results which is being submitted to the media, is also enclosed as **"Annexure B"**.

The disclosures for points (iii), (iv), (v), (vi) and (vii) above as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, are enclosed as **"Annexure C"**.

In terms of Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company will also publish an advertisement for Audited Standalone and Consolidated Financial Results for the fourth quarter and year ended March 31, 2026.

The above results along with audit report are also being made available on the website of the Company at www.coronaremedies.com

The Board meeting commenced at 2:30 p.m. and concluded at 4:00 p.m.

You are requested to take note of the above.

Thanking you.

Yours faithfully,

For CORONA Remedies Limited

Chetna Dharajiya
Company Secretary and Compliance Officer

Encl.: A/a

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL STANDALONE FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CORONA REMEDIES LIMITED (FORMERLY KNOWN AS CORONA REMEDIES PRIVATE LIMITED)

Opinion and Conclusion

We have (a) audited the Standalone Financial Results for the year ended March 31, 2026 and (b) reviewed the Standalone Financial Results for the quarter ended March 31, 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Standalone Financial Results for the Quarter and Year Ended March 31, 2026" of **CORONA REMEDIES LIMITED (FORMERLY KNOWN AS CORONA REMEDIES PRIVATE LIMITED)** (the "Company"), (the "Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Standalone Financial Results

In our opinion and to the best of our information and according to the explanations given to us, the Standalone Financial Results for the year ended March 31, 2026:

- i. are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- ii. gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and other comprehensive income and other financial information of the Company for the year then ended.

(b) Conclusion on Unaudited Standalone Financial Results for the quarter ended March 31, 2026

With respect to the Standalone Financial Results for the quarter ended March 31, 2026, based on our review conducted as stated in paragraph (b) of Auditor's Responsibilities section below, nothing has come to our attention that causes us to believe that the Standalone Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



Basis for Opinion on the Audited Standalone Financial Results for the year ended March 31, 2026

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Standalone Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement which includes the Standalone Financial Results is the responsibility of the Company's Board of Directors and has been approved by them for the issuance. The Standalone Financial Results for the year ended March 31, 2026 has been compiled from the related audited standalone financial statements. This responsibility includes the preparation and presentation of the Standalone Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the net profit and other comprehensive income and other financial information in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Results, the Board of Directors is responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors is also responsible for overseeing the financial reporting process of the Company.

Auditor's Responsibilities

(a) Audit of the Standalone Financial Results for the year ended March 31, 2026

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Standalone Financial Results.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Standalone Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Standalone Financial Results, including the disclosures, and whether the Annual Standalone Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Annual Standalone Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Standalone Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Standalone Financial Results.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



(b) Review of the Standalone Financial Results for the quarter ended March 31, 2026

We conducted our review of the Standalone Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements ("SRE") 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Other Matters

- The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report on the Statement is not modified in respect of this matter.
- The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year ended March 31, 2025 and audited special purpose interim financial statements for the nine months period ended 31 December 2024 which were not subject to limited review by us. Our report on the Statement is not modified in respect of this matter.

For DELOITTE HASKINS & SELLS LLP
Chartered Accountants
(Firm's Registration No.117366W/W-100018)



H. S. Sutaria

Hardik Sutaria
Partner
(Membership No.116642)
(UDIN: 26116642LYWESX7547)

Place: Ahmedabad
Date: May 11, 2026



CORONA Remedies Limited
 (formerly known as CORONA Remedies Private Limited)
 Regd. Office: CORONA House,
 C - Mondeal Business Park, Near Gurudwara, S.G.Highway,
 Thaltej, Ahmedabad-380059, Gujarat, India
 Tele.: +079-40233000 | Website : www.coronaremedies.com
 CIN : L24231GJ2004PLC044656

Statement of Standalone Financial Results for the Quarter and Year ended 31 March 2026

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Year Ended	
		31 Mar 2026 (Refer note 5)	31 Dec 2025 (Unaudited)	31 Mar 2025 (Refer note 4)	31 Mar 2026 (Audited)	31 Mar 2025 (Audited)
1	Income :					
a	Revenue from operations	353.09	342.42	293.69	1,403.18	1,196.42
b	Other income	4.11	2.24	1.42	10.65	5.93
	Total income	357.20	344.66	295.11	1,413.83	1,202.35
2	Expenses :					
a	Cost of materials consumed	27.73	24.82	25.89	103.51	102.29
b	Purchases of Stock-in-trade	46.34	41.15	45.78	150.38	157.97
c	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(7.83)	(5.70)	(14.81)	7.05	(23.74)
d	Employee benefits expense	106.63	95.94	84.85	403.02	346.14
e	Finance costs	1.38	1.66	2.20	6.97	10.60
f	Depreciation and amortization expenses	10.29	9.45	10.04	37.87	37.16
g	Other expenses	118.20	103.05	97.76	445.78	373.78
	Total expenses	302.74	270.37	251.71	1,154.58	1,004.20
3	Profit before Exceptional item and Tax (1-2)	54.46	74.29	43.40	259.25	198.15
4	Exceptional item :					
a	Statutory impact of new Labour Codes (Refer note 6)	-	(19.10)	-	(19.10)	-
5	Profit before tax (3+4)	54.46	55.19	43.40	240.15	198.15
6	Tax expense :					
a	Current tax expense	8.06	17.10	9.24	56.20	45.55
b	(Excess) provision for tax relating to earlier periods / year	(3.83)	-	-	(4.72)	(0.75)
c	Deferred tax expense / (income)	5.18	(3.16)	2.82	3.82	4.30
	Total Tax expense	9.41	13.94	12.06	55.30	49.10
7	Net Profit after tax for the period / year (5-6)	45.05	41.25	31.34	184.85	149.05
8	Other comprehensive income / (loss) for the period/year					
a	Items that will not be reclassified to profit and loss	0.90	(0.08)	(0.35)	0.15	(1.16)
b	Income tax effect on above item	(0.23)	0.02	0.09	(0.04)	0.29
	Total Other comprehensive income / (loss) for the period/year	0.67	(0.06)	(0.26)	0.11	(0.87)
9	Total comprehensive income for the period/year (7+8)	45.72	41.19	31.08	184.96	148.18
10	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16	61.16
11	Other Equity				684.81	544.56
12	Earnings per share (not annualised for the quarter)					
a	Basic (Rs.)	7.37	6.74	5.12	30.22	24.37
b	Diluted (Rs.)	7.37	6.74	5.12	30.22	24.37



Statement of Standalone Assets and Liabilities as at 31 March 2026
(Amount Rs. in Crores)

Sr. No.	Particulars	As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
A	ASSETS:		
1	Non-current assets		
a	Property, plant and equipment	291.14	198.73
b	Capital work-in-progress	143.12	185.95
c	Other intangible assets	262.83	171.15
d	Financial assets		
i	Investments	25.40	25.34
ii	Loans	0.01	0.03
iii	Other financial assets	129.87	1.25
e	Other non-current assets	3.57	7.92
	Total non-current assets	855.94	590.37
2	Current assets		
a	Inventories	125.00	129.48
b	Financial assets		
i	Trade receivables	145.55	118.29
ii	Cash and cash equivalents	1.83	3.22
iii	Bank balances other than cash and cash equivalents	42.29	66.05
iv	Loans	0.26	0.38
v	Other financial assets	0.30	2.64
c	Other current assets	33.08	18.81
	Total current assets	348.31	338.87
	TOTAL ASSETS	1,204.25	929.24
B	EQUITY AND LIABILITIES:		
1	Equity		
a	Equity share capital	61.16	61.16
b	Other equity	684.81	544.56
	Total equity	745.97	605.72
	Liabilities		
2	Non-current liabilities		
a	Financial liabilities		
i	Borrowings	-	16.00
ii	Lease liabilities	18.88	21.02
b	Provisions	66.07	38.61
c	Deferred tax liabilities (net)	12.16	8.30
	Total non-current liabilities	97.11	83.93
3	Current liabilities		
a	Financial liabilities		
i	Borrowings	142.86	46.70
ii	Lease liabilities	3.11	2.52
iii	Trade payables		
	- total outstanding dues of micro enterprises and small enterprises	9.85	2.91
	- total outstanding dues of creditors other than micro enterprise and small enterprise	137.22	140.61
iv	Other financial liabilities	19.72	4.77
b	Other current liabilities	6.99	8.37
c	Provisions	33.04	27.39
d	Current tax liabilities (net)	8.38	6.32
	Total current liabilities	361.17	239.59
	Total liabilities	458.28	323.52
	TOTAL EQUITY AND LIABILITIES	1,204.25	929.24



Statement of Standalone Cash Flows for the Year ended 31 March 2026 (Amount Rs. in Crores)		
Particulars	Year ended 31 March 2026 (Audited)	Year ended 31 March 2025 (Audited)
Cash flow from operating activities		
Profit before tax	240.15	198.15
Adjustments for:		
Depreciation and amortization expenses	37.87	37.16
Finance costs	6.97	10.60
Interest income	(7.06)	(4.41)
Income from sale of Investments (mutual funds) *	(0.00)	-
Fair valuation adjustments of Investments designated as Fair Value through Profit & Loss (FVTPL)	(0.07)	(0.02)
Loss on sale/disposal of fixed assets	0.54	0.71
(Written back) / provision for expected credit loss	0.05	(0.01)
(Written back) / provision for inventory obsolescence	(0.73)	2.25
Bad debts written off	0.18	0.06
Liabilities written back	(0.19)	(0.19)
Provision for expiry and breakage sales return	8.31	6.59
Net Unrealized exchange (Gain)	(1.25)	(0.05)
Operating profit before working capital changes	284.77	250.84
Changes in working capital		
Decrease / (Increase) in inventories	5.21	(33.39)
(Increase) in trade receivables	(26.21)	(18.36)
(Increase) / Decrease in other current assets	(14.27)	2.55
Decrease / (Increase) in other financial assets	2.36	(2.77)
Decrease in non-current assets	0.04	0.11
Decrease in loans	0.14	0.06
Increase in other financial liabilities	1.23	1.08
Increase in provisions	24.95	2.70
Increase in trade payables	3.71	29.42
(Decrease) / Increase in other current liabilities	(3.03)	1.53
Cash generated from operations	278.90	233.77
Income taxes paid (Net of Income Tax refund)	(49.42)	(43.28)
Net cash generated from operating activities (A)	229.48	190.49
Cash flow from Investing activities		
Payment for property, plant and equipment and other intangible assets including capital work-in-progress, capital advance and capital payable	(174.14)	(91.66)
Current investments not considered as Cash and cash equivalents-Net *	0.01	-
Proceeds from sale/ disposal of fixed assets	0.54	0.64
Fixed deposits placed with Bank not considered as Cash and cash equivalents-Net	(89.62)	2.75
Interest received	7.06	4.41
Net cash (used in) investing activities (B)	(256.15)	(83.86)
Cash flow from Financing activities		
Payment of dividend	(44.71)	(22.63)
Repayment of long-term borrowings	(36.00)	(51.00)
Proceeds from / (repayment) of working capital borrowings (net)	116.16	(20.44)
Interest paid	(5.26)	(7.82)
Payment towards lease liability (excluding interest)	(2.78)	(2.37)
Interest on lease liability	(2.13)	(2.31)
Net cash generated / (used in) from financing activities (C)	25.28	(106.57)
Net (decrease) / increase in cash and cash equivalents (A+B+C)	(1.39)	0.06
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents**	(0.00)	(0.00)
Cash and cash equivalents at the beginning of the year	3.22	3.16
Cash and cash equivalents at the end of the year	1.83	3.22

The above statement of cash flows excludes the proceeds received in the share escrow account amounting to Rs.655.37 Crores on account of offer for sale made by the selling shareholders. Book running lead manager disbursed Rs.583.53 Crores to its selling shareholders and Rs.56.58 Crores to various parties for initial public offer expenses. The remaining funds amounting to Rs.15.26 Crores which are yet to be paid to the selling shareholders after payments of initial public offer expenses is held in share escrow account.

* Income from sale of Investments (mutual funds) for the year ended 31 March 2026 represents amounting Rs.20,715/-.

** Effect of exchange differences on restatement of foreign currency Cash and cash equivalents for the year ended 31 March 2026 represents amounting Rs.20,714/- (Rs.2,478/- for the year ended 31 March 2025).

Particulars	Year ended 31 March 2026 (Audited)	Year ended 31 March 2025 (Audited)
Cash and cash equivalents comprise		
Balances with banks:		
In current accounts	0.05	0.52
Cheques on hand	1.70	2.67
Cash on hand	0.08	0.03
Total cash and bank balances at end of the year	1.83	3.22



Notes to Standalone Financial Results for the Quarter and Year ended 31 March 2026 :

- 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders.
- 2 The above standalone financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 11 May 2026.
- 3 These standalone financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 4 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures with respect to the full financial year for the year ended 31 March 2025 and audited special purpose interim financial statements for the nine months period ended 31 December 2024 which were prepared for IPO filings and have not been reviewed by the statutory auditors.
- 5 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended 31 December 2025 which were subjected to limited review.
- 6 **One time impact of New Labour Codes :**

On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" amounting Rs.19.10 crores (Post tax Rs.14.29 crores) in the financial results for the year ended 31 March 2026.

The incremental impact consisting of gratuity of Rs.13.60 crores and long-term compensated absences of Rs.5.50 crores primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

- 7 As at 31 March 2026, the Company held fixed deposits aggregating to Rs. 155.70 Crores (comprising Rs. 128.70 Crores under other non-current financial assets and Rs. 27.00 Crores under bank balances other than cash and cash equivalents), against which overdraft facilities amounting to Rs. 126.86 Crores were availed and disclosed under short-term borrowings.
- 8 The Board of Directors have recommended dividend of Rs.10/- per fully paid up equity share of Rs.10/- each for financial year ended 31 March 2026 on outstanding paid up share capital of the Company as on date, in its board meeting held on 11 May 2026, subject to approval of the shareholders at Annual General Meeting (AGM) of the Company.
- 9 The Company has only one reportable business segment i.e. 'Pharmaceuticals'.

For CORONA Remedies Limited,


Nirav K. Mehta
Managing Director & CEO
DIN : 01644041



Place: Ahmedabad
Date : 11 May 2026

INDEPENDENT AUDITOR'S REPORT ON AUDIT OF ANNUAL CONSOLIDATED FINANCIAL RESULTS AND REVIEW OF QUARTERLY FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF CORONA REMEDIES LIMITED (FORMERLY KNOWN AS CORONA REMEDIES PRIVATE LIMITED)

Opinion and Conclusion

We have (a) audited the Consolidated Financial Results for the year ended March 31, 2026 and (b) reviewed the Consolidated Financial Results for the quarter ended March 31, 2026 (refer 'Other Matters' section below), which were subject to limited review by us, both included in the accompanying "Statement of Consolidated Financial Results for the Quarter and Year Ended March 31, 2026" of **CORONA REMEDIES LIMITED (FORMERLY KNOWN AS CORONA REMEDIES PRIVATE LIMITED)** (the "Parent") and its share of the net profit after tax and other comprehensive income of its associate for the quarter and year ended March 31, 2026, (the "Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "LODR Regulations").

(a) Opinion on Annual Consolidated Financial Results

In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the audit report of the other auditor on separate financial statements of associate referred to in Other Matters section below, the Consolidated Financial Results for the year ended March 31, 2026:

- (i) includes the financial results of the following entities:
 - CORONA Remedies Limited- the Parent
 - La Chandra Pharamalab Private Limited -the Associate
- (ii) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended; and
- (iii) gives a true and fair view in conformity with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India of the consolidated net profit and consolidated other comprehensive income and other financial information of the Parent and its associate for the year ended March 31, 2026.



(b) Conclusion on Unaudited Consolidated Financial Results for the quarter ended March 31, 2026

With respect to the Consolidated Financial Results for the quarter ended March 31, 2026, based on our review conducted and procedures performed as stated in paragraph (b) of Auditor's Responsibilities section below and based on the consideration of the review report of the other auditor referred to in Other Matters section below, nothing has come to our attention that causes us to believe that the Consolidated Financial Results for the quarter ended March 31, 2026, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Basis for Opinion on the Audited Consolidated Financial Results for the year ended March 31, 2026

We conducted our audit in accordance with the Standards on Auditing ("SA"s) specified under Section 143(10) of the Companies Act, 2013 (the "Act"). Our responsibilities under those Standards are further described in paragraph (a) of Auditor's Responsibilities section below. We are independent of the Parent and its associate in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (the "ICAI") together with the ethical requirements that are relevant to our audit of the Consolidated Financial Results for the year ended March 31, 2026 under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditor in terms of their reports referred to in Other Matters section below, is sufficient and appropriate to provide a basis for our audit opinion.

Management's and Board of Directors' Responsibilities for the Statement

This Statement, which includes the Consolidated Financial Results is the responsibility of the Parent's Board of Directors and has been approved by them for the issuance. The Consolidated Financial Results for the year ended March 31, 2026, has been compiled from the related audited consolidated financial statements. This responsibility includes the preparation and presentation of the Consolidated Financial Results for the quarter and year ended March 31, 2026 that give a true and fair view of the consolidated net profit and consolidated other comprehensive income and other financial information of the Parent including its associate in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards, prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the LODR Regulations.

The respective Board of Directors of the Parent and of its associate are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Parent and its associate and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the respective financial results that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of this Consolidated Financial Results by the Directors of the Parent, as aforesaid.



In preparing the Consolidated Financial Results, the respective Board of Directors of the Parent and of its associate are responsible for assessing the ability of the respective entities to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate their respective entities or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the Parent and of its associate are responsible for overseeing the financial reporting process of the Parent and of its associate.

Auditor's Responsibilities

(a) Audit of the Consolidated Financial Results for the year ended March 31, 2026

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Results for the year ended March 31, 2026 as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Consolidated Financial Results.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Annual Consolidated Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Board of Directors.
- Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulation 33 of the LODR Regulations.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Parent and its associate to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Consolidated Financial Results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Parent and its associate to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Annual Consolidated Financial Results, including the disclosures, and whether the Annual Consolidated Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.



- Perform procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the LODR Regulations to the extent applicable.
- Obtain sufficient appropriate audit evidence regarding the Annual Standalone Financial Results of the Parent and its associate to express an opinion on the Annual Consolidated Financial Results. We are responsible for the direction, supervision and performance of the audit of financial information of the Parent included in the Annual Consolidated Financial Results of which we are the independent auditors. For the other entity included in the Annual Consolidated Financial Results, which has been audited by other auditor, such other auditor remain responsible for the direction, supervision and performance of the audit carried out by them. We remain solely responsible for our audit opinion.

Materiality is the magnitude of misstatements in the Annual Consolidated Financial Results that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Annual Consolidated Financial Results may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Annual Consolidated Financial Results.

We communicate with those charged with governance of the Parent and such other entity included in the Consolidated Financial Results of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

(b) Review of the Consolidated Financial Results for the quarter ended March 31, 2026

We conducted our review of the Consolidated Financial Results for the quarter ended March 31, 2026 in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the ICAI. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with SAs specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

The Statement includes the results of the entities as listed under paragraph (a)(i) of Opinion and Conclusion section above.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



Other Matters

- The Statement includes the results for the quarter ended March 31, 2025 being the balancing figure between audited figures in respect of the full financial year ended March 31, 2025 and audited special purpose interim financial statements for the nine months period ended 31 December 2024 which were not subject to limited review by us. Our report on the Statement is not modified in respect of this matter.
- The Statement includes the results for the quarter ended March 31, 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us. Our report is not modified in respect of this matter.
- The consolidated financial results includes the share of profit after tax of Rs.0.28 Crores and Rs. 0.27 Crores for the quarter and year ended March 31, 2026 respectively and other comprehensive income of Rs.0.28 Crores and Rs.0.27 Crores for the quarter and year ended March 31, 2026 respectively, as considered in the Statement, in respect of one associate, whose financial statements have not been audited by us. These financial statements have been audited as applicable, by other auditor whose reports have been furnished to us by the Management and our opinion and conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associate, is based solely on the report of the other auditor and the procedures performed by us as stated under Auditor's Responsibilities section above.

Our report on the Statement is not modified in respect of the above matter with respect to our reliance on the work done and the report of the other auditor.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)



H. S. Sutaria

Hardik Sutaria
Partner
(Membership No.116642)
(UDIN: 26116642NJKHVF1956)

Place: Ahmedabad
Date: May 11, 2026



CORONA Remedies Limited
(formerly known as CORONA Remedies Private Limited)
Regd. Office: CORONA House,
C - Mondeal Business Park, Near Gurudwara, S.G.Highway,
Thaltej, Ahmedabad-380059, Gujarat, India
Tele.: +079-40233000 | Website : www.coronaremedies.com
CIN : L24231GJ2004PLC044656

Statement of Consolidated Financial Results for the Quarter and Year ended 31 March 2026

(Amount Rs. in Crores except per share data)

Sr. No.	Particulars	For Quarter Ended			For Year Ended	
		31 Mar 2026 (Refer note 5)	31 Dec 2025 (Unaudited)	31 Mar 2025 (Refer note 4)	31 Mar 2026 (Audited)	31 Mar 2025 (Audited)
1	Income :					
a	Revenue from operations	353.09	342.42	293.69	1,403.18	1,196.42
b	Other income	4.11	2.24	1.42	10.65	5.93
	Total income	357.20	344.66	295.11	1,413.83	1,202.35
2	Expenses :					
a	Cost of materials consumed	27.73	24.82	25.89	103.51	102.29
b	Purchases of Stock-in-trade	46.34	41.15	45.78	150.38	157.97
c	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(7.83)	(5.70)	(14.81)	7.05	(23.74)
d	Employee benefits expense	106.63	95.94	84.85	403.02	346.14
e	Finance costs	1.38	1.66	2.20	6.97	10.60
f	Depreciation and amortization expenses	10.29	9.45	10.04	37.87	37.16
g	Other expenses	118.20	103.05	97.76	445.78	373.78
	Total expenses	302.74	270.37	251.71	1,154.58	1,004.20
3	Profit before Share of Profit of associate, Exceptional item and Tax (1-2)	54.46	74.29	43.40	259.25	198.15
4	Exceptional item :					
a	Statutory impact of new Labour Codes (Refer note 6)	-	(19.10)	-	(19.10)	-
5	Share of profit of associate (net of tax)	0.28	0.02	0.21	0.27	0.38
6	Profit before tax (3+4+5)	54.74	55.21	43.61	240.42	198.53
7	Tax expense :					
a	Current tax expense	8.06	17.10	9.24	56.20	45.55
b	(Excess) provision for tax relating to earlier periods / year	(3.83)	-	-	(4.72)	(0.75)
c	Deferred tax expense / (income)	5.18	(3.16)	2.82	3.82	4.30
	Total Tax expense	9.41	13.94	12.06	55.30	49.10
8	Net Profit after tax for the period / year (6-7)	45.33	41.27	31.55	185.12	149.43
9	Other comprehensive income / (loss) for the period/year					
a	Items that will not be reclassified to profit and loss	0.90	(0.08)	(0.35)	0.15	(1.16)
b	Income tax effect on above item	(0.23)	0.02	0.09	(0.04)	0.29
	Total Other comprehensive income / (loss) for the period/year	0.67	(0.06)	(0.26)	0.11	(0.87)
10	Total comprehensive income for the period/year (8+9)	46.00	41.21	31.29	185.23	148.56
11	Profit for the year/period attributable to:					
	Owners of the Company	45.33	41.27	31.55	185.12	149.43
		45.33	41.27	31.55	185.12	149.43
12	Total Other Comprehensive income / (loss) for the period/year attributable to:					
	Owners of the Company	0.67	(0.06)	(0.26)	0.11	(0.87)
		0.67	(0.06)	(0.26)	0.11	(0.87)
13	Total Comprehensive income for the period/year attributable to:					
	Owners of the Company	46.00	41.21	31.29	185.23	148.56
		46.00	41.21	31.29	185.23	148.56
14	Paid-up equity share capital (face value Rs.10/-)	61.16	61.16	61.16	61.16	61.16
15	Other Equity				685.70	545.18
16	Earnings per share (not annualised for the quarter)					
a	Basic (Rs.)	7.41	6.75	5.16	30.27	24.43
b	Diluted (Rs.)	7.41	6.75	5.16	30.27	24.43



Statement of Consolidated Assets and Liabilities as at 31 March 2026

(Amount Rs. in Crores)

Sr. No.	Particulars	As at 31 March 2026 (Audited)	As at 31 March 2025 (Audited)
A	ASSETS:		
1	Non-current assets		
a	Property, plant and equipment	291.14	198.73
b	Capital work-in-progress	143.12	185.95
c	Other intangible assets	262.83	171.15
d	Investments accounted using equity method	26.12	25.85
e	Financial assets		
i	Investments	0.17	0.11
ii	Loans	0.01	0.03
iii	Other financial assets	129.87	1.25
f	Other non-current assets	3.57	7.92
	Total non-current assets	856.83	590.99
2	Current assets		
a	Inventories	125.00	129.48
b	Financial assets		
i	Trade receivables	145.55	118.29
ii	Cash and cash equivalents	1.83	3.22
iii	Bank balances other than cash and cash equivalents	42.29	66.05
iv	Loans	0.26	0.38
v	Other financial assets	0.30	2.64
c	Other current assets	33.08	18.81
	Total current assets	348.31	338.87
	TOTAL ASSETS	1,205.14	929.86
B	EQUITY AND LIABILITIES:		
1	Equity		
a	Equity share capital	61.16	61.16
b	Other equity	685.70	545.18
	Total equity	746.86	606.34
2	Non-current liabilities		
a	Financial liabilities		
i	Borrowings	-	16.00
ii	Lease liabilities	18.88	21.02
b	Provisions	66.07	38.61
c	Deferred tax liabilities (net)	12.16	8.30
	Total non-current liabilities	97.11	83.93
3	Current liabilities		
a	Financial liabilities		
i	Borrowings	142.86	46.70
ii	Lease liabilities	3.11	2.52
iii	Trade payables		
	- total outstanding dues of micro enterprises and small enterprises	9.85	2.91
	- total outstanding dues of creditors other than micro enterprise and small enterprise	137.22	140.61
iv	Other financial liabilities	19.72	4.77
b	Other current liabilities	6.99	8.37
c	Provisions	33.04	27.39
d	Current tax liabilities (net)	8.38	6.32
	Total current liabilities	361.17	239.59
	Total liabilities	458.28	323.52
	TOTAL EQUITY AND LIABILITIES	1,205.14	929.86



Statement of Consolidated Cash Flows for the Year ended 31 March 2026
(Amount Rs. in Crores)

Particulars	Year ended 31 March 2026 (Audited)	Year ended 31 March 2025 (Audited)
Cash flow from operating activities		
Profit before tax	240.42	198.53
Adjustments for:		
Share of (profit) from Associate	(0.27)	(0.38)
Depreciation and amortization expenses	37.87	37.16
Finance costs	6.97	10.60
Interest income	(7.06)	(4.41)
Income from sale of Investments (mutual funds) *	(0.00)	-
Fair valuation adjustments of Investments designated as Fair Value through Profit & Loss (FVTPL)	(0.07)	(0.02)
Loss on sale/disposal of fixed assets	0.54	0.71
(Written back) / provision for expected credit loss	0.05	(0.01)
(Written back) / provision for inventory obsolescence	(0.73)	2.25
Bad debts written off	0.18	0.06
Liabilities written back	(0.19)	(0.19)
Provision for expiry and breakage sales return	8.31	6.59
Net Unrealized exchange (Gain)	(1.25)	(0.05)
Operating profit before working capital changes	284.77	250.84
Changes in working capital		
Decrease / (Increase) in inventories	5.21	(33.39)
(Increase) in trade receivables	(26.21)	(18.36)
(Increase) / Decrease in other current assets	(14.27)	2.55
Decrease / (Increase) in other financial assets	2.36	(2.77)
Decrease in non-current assets	0.04	0.11
Decrease in loans	0.14	0.06
Increase in other financial liabilities	1.23	1.08
Increase in provisions	24.95	2.70
Increase in trade payables	3.71	29.42
(Decrease) / Increase in other current liabilities	(3.03)	1.53
Cash generated from operations	278.90	233.77
Income taxes paid (Net of Income Tax refund)	(49.42)	(43.28)
Net cash generated from operating activities (A)	229.48	190.49
Cash flow from Investing activities		
Payment for property, plant and equipment and other intangible assets including capital work-in-progress, capital advance and capital payable	(174.14)	(91.66)
Current investments not considered as Cash and cash equivalents-Net *	0.01	-
Proceeds from sale/ disposal of fixed assets	0.54	0.64
Fixed deposits placed with Bank not considered as Cash and cash equivalents-Net	(89.62)	2.75
Interest received	7.06	4.41
Net cash (used in) investing activities (B)	(256.15)	(83.86)
Cash flow from Financing activities		
Payment of dividend	(44.71)	(22.63)
Repayment of long-term borrowings	(36.00)	(51.00)
Proceeds from / (repayment) of working capital borrowings (net)	116.16	(20.44)
Interest paid	(5.26)	(7.82)
Payment towards lease liability (excluding interest)	(2.78)	(2.37)
Interest on lease liability	(2.13)	(2.31)
Net cash generated / (used in) from financing activities (C)	25.28	(106.57)
Net (decrease) / increase in cash and cash equivalents (A+B+C)	(1.39)	0.06
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents**	(0.00)	(0.00)
Cash and cash equivalents at the beginning of the year	3.22	3.16
Cash and cash equivalents at the end of the year	1.83	3.22

The above statement of cash flows excludes the proceeds received in the share escrow account amounting to Rs.655.37 Crores on account of offer for sale made by the selling shareholders. Book running lead manager disbursed Rs.583.53 Crores to its selling shareholders and Rs.56.58 Crores to various parties for initial public offer expenses. The remaining funds amounting to Rs.15.26 Crores which are yet to be paid to the selling shareholders after payments of initial public offer expenses is held in share escrow account.

* Income from sale of Investments (mutual funds) for the year ended 31 March 2026 represents amounting Rs.20,715/-.

** Effect of exchange differences on restatement of foreign currency Cash and cash equivalents for the year ended 31 March 2026 represents amounting Rs.20,714/- (Rs.2,478/- for the year ended 31 March 2025).

Particulars	Year ended 31 March 2026 (Audited)	Year ended 31 March 2025 (Audited)
Cash and cash equivalents comprise		
Balances with banks:		
In current accounts	0.05	0.52
Cheques on hand	1.70	2.67
Cash on hand	0.08	0.03
Total cash and bank balances at end of the year	1.83	3.22



Notes to Consolidated Financial Results for the Quarter and Year ended 31 March 2026 :

- 1 The Company's equity shares have been listed on the National Stock Exchange of India ("NSE") and on BSE Limited ("BSE") on 15 December, 2025, by completing Initial Public Offering through offer for sale of 61,74,051 equity shares of face value of Rs.10 each at an issue price of Rs.1,008 per equity share (for employees) and Rs.1,062 per equity share (other than employees) by selling shareholders. The total initial public offer expenses (except listing fees) are entirely allocated to the selling shareholders.
- 2 The above consolidated financial results have been reviewed by the Audit Committee and subsequently approved by Board of Directors at their respective meetings held on 11 May 2026.
- 3 These consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 ["Ind AS"] as prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India [Listing Obligations and Disclosure Requirements] Regulations, 2015, as amended.
- 4 The figures for the quarter ended 31 March 2025 are the balancing figures between the audited figures with respect to the full financial year for the year ended 31 March 2025 and audited special purpose interim financial statements for the nine months period ended 31 December 2024 which were prepared for IPO filings and have not been reviewed by the statutory auditors.
- 5 The figures for the quarter ended 31 March 2026 are the balancing figures between the audited figures with respect to the full financial year and the published unaudited year to date figures upto the third quarter ended 31 December 2025 which were subjected to limited review.

6 One time impact of New Labour Codes :

On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Ministry of Labour & Employment published draft Central Rules and FAQs to enable assessment of the financial impact due to changes in regulations. The Company has assessed and disclosed the incremental impact of these changes on the basis of the guidance provided by the Institute of Chartered Accountants of India. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company has presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" amounting Rs.19.10 crores (Post tax Rs.14.29 crores) in the financial results for the year ended 31 March 2026.

The incremental impact consisting of gratuity of Rs.13.60 crores and long-term compensated absences of Rs.5.50 crores primarily arises due to change in wage definition. The Company continues to monitor the finalisation of Central / State Rules and clarifications from the Government on other aspects of the Labour Code and would provide appropriate accounting effect on the basis of such developments as needed.

- 7 As at 31 March 2026, the Company held fixed deposits aggregating to Rs. 155.70 Crores (comprising Rs. 128.70 Crores under other non-current financial assets and Rs. 27.00 Crores under bank balances other than cash and cash equivalents), against which overdraft facilities amounting to Rs. 126.86 Crores were availed and disclosed under short-term borrowings.
- 8 The Board of Directors have recommended dividend of Rs.10/- per fully paid up equity share of Rs.10/- each for financial year ended 31 March 2026 on outstanding paid up share capital of the Company as on date, in its board meeting held on 11 May 2026, subject to approval of the shareholders at Annual General Meeting (AGM) of the Company.
- 9 The Company and its associate has only one reportable business segment i.e. 'Pharmaceuticals'.

For CORONA Remedies Limited,



Nirav K. Mehta
Managing Director & CEO
DIN : 01644041

Place: Ahmedabad
Date : 11 May 2026



Annexure B

PRESS RELEASE

CORONA Remedies reports strong Revenue growth of 17.3% & PAT¹ growth of 33.4% in FY 2026 on a Y-o-Y basis; driven by Strong Brand Building initiatives & Execution Excellence

Ahmedabad | May 11, 2026

CORONA Remedies Limited, leading India-focused branded pharmaceutical company, announced its audited financial results for **Q4FY26 & FY26**, showcasing **robust financial performance driven by strong brand-building initiatives, portfolio expansion, and operational efficiencies.**

◇ Key Highlights

- **Revenue Growth:** Achieved **20.2% YoY growth in Q4FY26 and 17.3% growth in FY26**, driven by focused brand-building initiatives.
- **Margin growth:** **Q4FY26 & FY26 PAT¹** grew by **43.7% & 33.4%** respectively supported by **operating leverage and cost optimization.**
- **Strategic Acquisition:** Acquired **WOKADINE** marking entry into the **₹648 Cr Povidone Iodine market.** Acquisition has been funded through internal accruals.
- **Portfolio Expansion:** Relaunched key brands—Fostine R and Menodac under Women’s Health Therapeutics, and Noklot in the Cardiovascular segment—thereby expanding the addressable market.
- **Infertility Segment Focus:** Established a dedicated team to capture high-growth specialty segment.
- **Brand Strength:** Achieved milestone of **2 brands crossing ₹100 Cr MAT revenue (March 26)**, reflecting strong brand equity.
- **Industry Ranking:** Improved market position to **27th rank in India**; consistently moving **5 spots ahead in last 3 years.**

◇ Financial Performance Snapshot

Particulars (₹ Cr)	Q4FY26	Q4FY25	Y-o-Y	FY26	FY25	Y-o-Y
Revenue from Operations	353.1	293.7	20.2%	1,403.2	1,196.4	17.3%
EBITDA	62.0	54.2	14.4%	293.4	240.0	22.3%
EBITDA Margin	17.6%	18.5%	(89) bps	20.9%	20.1%	85 bps
Profit After Tax ¹	45.3	31.5	43.7%	199.4	149.4	33.4%
PAT Margin ¹	12.8%	10.7%	210 bps	14.2%	12.5%	172 bps

¹Includes one-time statutory impact of New Labor Code ₹19.1 Crores (Post Tax ₹14.3 Crores) in FY26

◇ Management Commentary

Mr. Nirav K. Mehta, Managing Director & CEO, CORONA Remedies Limited, said:

'FY26 has been a strong year for CORONA Remedies, marked by consistent revenue growth and enhanced operational efficiency. Our strategic focus on **brand building, specialty segments like biosimilars and infertility and portfolio expansion through acquisitions** continues to strengthen our competitive positioning.

With strategic initiatives like acquisition of WOKADINE and global accreditations, we are well-positioned to drive sustainable growth in years to come.'

◇ Business Highlights

Strategic Acquisitions & Portfolio Expansion

- Entry into **Povidone Iodine market** through WOKADINE acquisition.
- Leveraging **Bayer-Zyodus portfolio** through relaunch of key brands.

Market Positioning & Growth

- Improved **industry ranking to 27th** from 32nd in last three years.
- Chronic therapies continued to perform well, contributing **~72.3% & 71.9%** of total Revenue in Q4FY26 and FY26 respectively.

Manufacturing and R&D Excellence

- **EAEU-GMP certification** enables entry into **Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan** markets.

About CORONA Remedies Limited

Founded in 2004, CORONA Remedies Limited is a leading India-focused pharmaceutical company engaged in developing, manufacturing, and marketing products across key therapeutic areas including women's healthcare, cardio-diabetes, pain management, and urology. The company operates WHO-GMP/EU GMP-certified manufacturing facilities and maintains strong innovation capabilities through DSIR-approved R&D centers.

Safe Harbor

This document may contain forward-looking statements about CORONA Remedies Limited which are based on the beliefs, opinions, and expectations of the company's management as the date of this Investor release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.

For further information please contact

Company	Investor Relations Advisors
CORONA Remedies Limited CIN No: L24231GJ2004PLC044656 Chetna Dharajiya – Company Secretary & Compliance Officer investor@coronaremedies.com	Strategic Growth Advisors Pvt Ltd. CIN No: U74140MH2010PTC204285 Sagar Shroff / Tanay Shah Email id: sagar.shroff@sgapl.net / tanay.shah@sgapl.net Tel No: +91 98205 19303 / +91 98333 91899

Annexure C

Details as required in accordance with SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

(iii) Details of Statutory Auditor:

PARTICULARS	DETAILS
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of M/s. Walker Chandiook & Co LLP, (Firm Registration Number: 001076N/N500013) Chartered Accountants, as the Statutory Auditor of the Company.
Date of appointment /re-appointment/cessation (as applicable) & term of appointment/ re-appointment	May 11, 2026 Terms of appointment: Appointment at the Board Meeting held on May 11, 2026 for a period of five (5) consecutive years commencing from conclusion of the 22nd Annual General Meeting to be held for the financial year 2025-26 until the conclusion of the 27th Annual General Meeting to be held for the financial year 2030-31, subject to the approval of shareholders of the Company at the ensuing Annual General Meeting.
Brief profile (in case of appointment);	M/s. Walker Chandiook & Co LLP (Firm Registration no. 001076N/N500013) is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India (ICAI), Public Company Accounting Oversight Board (PCAOB) and empanelled with Comptroller and Auditor General of India (CAG). The firm was established in the year 1935 and its registered office is situated at New Delhi with Eighteen other offices across major cities in India. It has eighty-six partners. It has a valid peer review certificate and is one of India's leading audit firms providing audit and assurance services to several large companies including some of the top one hundred listed entities in India.
Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Details as required in accordance with SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

(iv) Details of Secretarial Auditor:

PARTICULARS	DETAILS
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment of Dhara Panara (ACS No. 29198 / C.P. No. 10979), Proprietor of M/s. Dhara Patel, Practicing Company Secretary, Ahmedabad, as the Secretarial Auditor of the Company.
Date of appointment / re-appointment/cessation (as applicable) & term of appointment/re- appointment	May 11, 2026 Terms of re-appointment: Re-appointment as Secretarial Auditor for a period of five consecutive years commencing from the financial year 2026-27, subject to approval of Members at the ensuing Annual General Meeting of the Company.
Brief profile;	Dhara Panara is the proprietor of M/s. Dhara Patel, Practicing Company Secretary and possesses over 14 years of experience in the field of corporate laws, securities laws, secretarial compliances and corporate governance matters.
Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Details as required in accordance with SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

(v) Details of Internal Auditor:

PARTICULARS	DETAILS
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment of M/s. Shah & Shah Associates, Chartered Accountants, Ahmedabad as the Internal Auditors of the Company.
Date of appointment / re-appointment/cessation (as applicable) & term of appointment/re-appointment	May 11, 2026 Terms of appointment: Appointment as Internal Auditor at the Board Meeting held on May 11, 2026, for the financial year 2026-27.
Brief profile (in case of appointment);	<p>M/s. Shah & Shah Associates established in 1978 (Firm Registration No.113742W) is Ahmedabad based Chartered Accountant firm. The firm provides professional services in the areas of audit, internal audits, tax audits, VAT/GST audits, transfer pricing and direct tax matters.</p> <p>The firm has a clientele across various sectors such as Manufacturing, Pharmaceuticals, Chemicals and Fast Moving Consumer Goods (FMCG).</p> <p>The Firm is led by experienced partners and supported by a dedicated professional team committed to maintaining high standards of professionalism and quality client services.</p>
Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Details as required in accordance with SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

(vi) Details of Cost Auditor:

PARTICULARS	DETAILS
Reason for change viz. appointment , re-appointment, resignation , removal , death or otherwise;	Re-appointment of M/s. Manish B. Analkat, Cost Accountants, Ahmedabad (Registration No. 19378) as the Cost Auditors of the Company.
Date of appointment / re appointment/ cessation (as applicable) & term of appointment /re- appointment	May 11, 2026 Terms of re-appointment: Re-appointment as Cost Auditor for the financial year 2026-27
Brief profile;	Having 26 years of experience in cost accounting fields such as system analysis, installation, development of cost accounts, internal audits, bank audit etc., in the following industries: Pharmaceutical, Textile, Mining, Drugs (Bulk Drugs, Formulations, Industrial Alcohol, Cosmetics, Poultry Vaccines), Engineering Products, Electricity, Gas Distribution, Telecommunication, Agriculture, Construction, etc.
Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Details as required in accordance with SEBI Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

(vii) Details of Director re-appointed:

PARTICULARS	DETAILS
Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment as Non-Executive Director and Chairman for a term of five (5) consecutive financial years with effect from April 01, 2027, subject to the approval of the shareholders at the ensuing Annual General Meeting.
Date of appointment / re-appointment/ cessation (as applicable) & term of appointment /re-appointment	The re-appointment as Non-Executive Director and Chairman at the Board Meeting held on May 11, 2026, shall be effective from April 01, 2027 and it is subject to approval of the Members at the ensuing Annual General Meeting.
Brief profile (in case of appointment);	<p>Dr. Kirtikumar Mehta is one of the Promoters and Non-Executive Director, Chairman of the Company. He has been associated with the Company since incorporation. He holds a bachelor's degree in medicine and surgery from Gujarat University, Ahmedabad, Gujarat. He has over 36 years of experience in the medical and pharmaceutical industry.</p> <p>He specializes in international business strategy, process optimization, and global market expansion, among other areas. His operational leadership is characterized by strategic vision, adaptability, and an uncompromising commitment to excellence. With a focus on precision and detail, he guides continuous improvement and innovation, cultivating a collaborative culture that strengthens the organization's global presence.</p> <p>He serves as a strategic visionary and chief mentor for global operations, he provides invaluable guidance to drive the organization's growth and international presence.</p>
Disclosure of relationships between directors (in case of appointment of a director).	Dr. Kirtikumar Mehta, Non-Executive Director and Chairman of the Company is related to Mr. Nirav Mehta, Managing Director and Chief Executive Officer and Mr. Ankur Mehta, Joint Managing Director as father.